NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Price, Quote, News and Summary
NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR
NVO Quote and Key Statistics
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (1/17/2025, 8:18:23 PM)
After market: 78.9 +0.21 (+0.27%)78.69
-4.38 (-5.27%)
NVO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 35.01% | ||
| ROA | 23.83% | ||
| ROE | 78.59% | ||
| Debt/Equity | 0.43 |
NVO Performance and Technical Analysis
NVO Ownership and Analysts
NVO Latest News and Analysis
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing good growth, while it is not too expensive.
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
Is Novo Nordisk Stock a Buy?
Is Novo Nordisk Stock a Buy?
It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same pace it has been recently, its blockbuster drugs, specifically its weight loss drug Wegovy, need to continue to retain a sizable share of the market.
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
About NVO
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880 DK
CEO: Lars Fruergaard Jorgensen
Employees: 69260
Company Website: https://www.novonordisk.com/
Investor Relations: https://www.novonordisk.com/investors.html
Phone: 4544448888
NVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| SNY | SANOFI-ADR | 12.29 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.88 | 24.83B |